139 related articles for article (PubMed ID: 8001030)
1. Histamine in immunotherapy of advanced melanoma: a pilot study.
Hellstrand K; Naredi P; Lindner P; Lundholm K; Rudenstam CM; Hermodsson S; Asztély M; Hafström L
Cancer Immunol Immunother; 1994 Dec; 39(6):416-9. PubMed ID: 8001030
[TBL] [Abstract][Full Text] [Related]
2. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
[TBL] [Abstract][Full Text] [Related]
3. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
4. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
[TBL] [Abstract][Full Text] [Related]
6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Schmidt H; Larsen S; Bastholt L; Fode K; Rytter C; Von Der Maase H
Ann Oncol; 2002 Dec; 13(12):1919-24. PubMed ID: 12453861
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
9. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
14. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma.
Bafaloukos D; Fountzilas G; Skarlos D; Pavlidis N; Bakoyiannis C; Karvounis N; Kosmidis P
Oncology; 1998; 55(1):48-52. PubMed ID: 9428375
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
19. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
